tiprankstipranks
Trending News
More News >
Neumora Therapeutics, Inc. (NMRA)
:NMRA
US Market

Neumora Therapeutics, Inc. (NMRA) Stock Forecast & Price Target

Compare
291 Followers
See the Price Targets and Ratings of:

NMRA Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
3 Buy
3 Hold
1 Sell
Based on 7 analysts giving stock ratings to
Neumora
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NMRA Stock 12 Month Forecast

Average Price Target

$5.67
▲(666.22%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Neumora Therapeutics, Inc. in the last 3 months. The average price target is $5.67 with a high forecast of $18.00 and a low forecast of $1.00. The average price target represents a 666.22% change from the last price of $0.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4,9,14,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,2.0953846153846154,3.420769230769231,4.746153846153846,6.071538461538461,7.396923076923077,8.722307692307693,10.047692307692307,11.373076923076923,12.698461538461538,14.023846153846154,15.349230769230768,16.674615384615386,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,1.146923076923077,1.5238461538461539,1.900769230769231,2.277692307692308,2.6546153846153846,3.031538461538462,3.408461538461539,3.785384615384616,4.162307692307692,4.53923076923077,4.916153846153847,5.293076923076924,{"y":5.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7876923076923077,0.8053846153846154,0.823076923076923,0.8407692307692308,0.8584615384615385,0.8761538461538462,0.8938461538461538,0.9115384615384615,0.9292307692307693,0.946923076923077,0.9646153846153847,0.9823076923076923,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.1,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.94,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$18.00Average Price Target$5.67Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on NMRA
Graig SuvannavejhMizuho Securities
Mizuho Securities
$4
Buy
440.54%
Upside
Reiterated
05/23/25
Mizuho Securities Sticks to Their Buy Rating for Neumora Therapeutics, Inc. (NMRA)
H.C. Wainwright Analyst forecast on NMRA
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$18
Buy
2332.43%
Upside
Reiterated
05/13/25
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating
William Blair Analyst forecast on NMRA
Myles MinterWilliam Blair
William Blair
Hold
Reiterated
05/13/25
William Blair Keeps Their Hold Rating on Neumora Therapeutics, Inc. (NMRA)
Needham Analyst forecast on NMRA
Ami FadiaNeedham
Needham
$5
Buy
575.68%
Upside
Reiterated
05/13/25
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements
RBC Capital Analyst forecast on NMRA
Brian AbrahamsRBC Capital
RBC Capital
$4
Hold
440.54%
Upside
Reiterated
05/12/25
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NASDAQ: NMRA), Aurinia Pharmaceuticals (NASDAQ: AUPH) and RegenXBio (NASDAQ: RGNX)
Bank of America Securities Analyst forecast on NMRA
Tazeen AhmadBank of America Securities
Bank of America Securities
$1
Sell
35.14%
Upside
Downgraded
04/01/25
Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study
Stifel Nicolaus Analyst forecast on NMRA
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$6$2
Hold
170.27%
Upside
Downgraded
03/07/25
Cautious Hold Rating on Neumora Therapeutics Amid Efficacy Concerns and Clinical Trial Setbacks
J.P. Morgan Analyst forecast on NMRA
Tessa RomeroJ.P. Morgan
J.P. Morgan
Hold
Reiterated
01/02/25
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
Citi
$22
Buy
2872.97%
Upside
Reiterated
06/06/24
Analysts Are Bullish on These Healthcare Stocks: Halozyme (HALO), 4D Molecular Therapeutics (FDMT)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on NMRA
Graig SuvannavejhMizuho Securities
Mizuho Securities
$4
Buy
440.54%
Upside
Reiterated
05/23/25
Mizuho Securities Sticks to Their Buy Rating for Neumora Therapeutics, Inc. (NMRA)
H.C. Wainwright Analyst forecast on NMRA
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$18
Buy
2332.43%
Upside
Reiterated
05/13/25
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating
William Blair Analyst forecast on NMRA
Myles MinterWilliam Blair
William Blair
Hold
Reiterated
05/13/25
William Blair Keeps Their Hold Rating on Neumora Therapeutics, Inc. (NMRA)
Needham Analyst forecast on NMRA
Ami FadiaNeedham
Needham
$5
Buy
575.68%
Upside
Reiterated
05/13/25
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements
RBC Capital Analyst forecast on NMRA
Brian AbrahamsRBC Capital
RBC Capital
$4
Hold
440.54%
Upside
Reiterated
05/12/25
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NASDAQ: NMRA), Aurinia Pharmaceuticals (NASDAQ: AUPH) and RegenXBio (NASDAQ: RGNX)
Bank of America Securities Analyst forecast on NMRA
Tazeen AhmadBank of America Securities
Bank of America Securities
$1
Sell
35.14%
Upside
Downgraded
04/01/25
Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study
Stifel Nicolaus Analyst forecast on NMRA
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$6$2
Hold
170.27%
Upside
Downgraded
03/07/25
Cautious Hold Rating on Neumora Therapeutics Amid Efficacy Concerns and Clinical Trial Setbacks
J.P. Morgan Analyst forecast on NMRA
Tessa RomeroJ.P. Morgan
J.P. Morgan
Hold
Reiterated
01/02/25
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
Citi
$22
Buy
2872.97%
Upside
Reiterated
06/06/24
Analysts Are Bullish on These Healthcare Stocks: Halozyme (HALO), 4D Molecular Therapeutics (FDMT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neumora Therapeutics, Inc.

1 Month
xxx
Success Rate
3/8 ratings generated profit
38%
Average Return
-6.08%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of -6.08% per trade.
3 Months
xxx
Success Rate
3/8 ratings generated profit
38%
Average Return
-23.00%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -23.00% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
1/8 ratings generated profit
13%
Average Return
-55.01%
reiterated a buy rating 24 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -55.01% per trade.
2 Years
xxx
Success Rate
1/8 ratings generated profit
13%
Average Return
-55.01%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -55.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NMRA Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
9
9
12
11
10
Buy
4
2
3
1
1
Hold
3
2
5
3
5
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
16
13
20
16
17
In the current month, NMRA has received 11 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. NMRA average Analyst price target in the past 3 months is 5.67.
Each month's total comprises the sum of three months' worth of ratings.

NMRA Financial Forecast

NMRA Earnings Forecast

Next quarter’s earnings estimate for NMRA is -$0.37 with a range of -$0.44 to -$0.33. The previous quarter’s EPS was -$0.42. NMRA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year NMRA has Outperformed its overall industry.
Next quarter’s earnings estimate for NMRA is -$0.37 with a range of -$0.44 to -$0.33. The previous quarter’s EPS was -$0.42. NMRA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year NMRA has Outperformed its overall industry.
No data currently available

NMRA Sales Forecast

Next quarter’s sales forecast for NMRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NMRA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year NMRA has Preformed in-line its overall industry.
Next quarter’s sales forecast for NMRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NMRA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year NMRA has Preformed in-line its overall industry.

NMRA Stock Forecast FAQ

What is NMRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Neumora Therapeutics, Inc.’s 12-month average price target is 5.67.
    What is NMRA’s upside potential, based on the analysts’ average price target?
    Neumora Therapeutics, Inc. has 666.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NMRA a Buy, Sell or Hold?
          Neumora Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 3 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Neumora Therapeutics, Inc.’s price target?
            The average price target for Neumora Therapeutics, Inc. is 5.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $18.00 ,the lowest forecast is $1.00. The average price target represents 666.22% Increase from the current price of $0.74.
              What do analysts say about Neumora Therapeutics, Inc.?
              Neumora Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of NMRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis